Home>REGULATORY

3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing(May.17.2017)
FPMAJ Chairman Masayo Tada (left), JPMA President Yoshihiko Hatanaka |
Three major pharma trade groups of Japan, the US, and Europe all pressed for a scheme to keep NHI drug prices for the duration of the patent term at a hearing of a key drug pricing panel on May 17 - aiming to turn the tide amid a growing headwind for the so-called price maintenance premium ...
(LOG IN FOR FULL STORY)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR Apr.20
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official Apr.19
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab Apr.17
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey Apr.17
-
Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
Apr.17